|
May 12
|
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
|
May 10
|
Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
|
|
May 10
|
Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 8
|
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
|
|
May 2
|
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
|
|
May 2
|
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
May 1
|
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
|
|
Apr 24
|
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
|
|
Apr 23
|
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
|
|
Apr 1
|
Investors bid Arcus Biosciences (NYSE:RCUS) up US$219m despite increasing losses YoY, taking five-year CAGR to 8.1%
|
|
Mar 29
|
Insider Sell: COO Jennifer Jarrett Sells 11,551 Shares of Arcus Biosciences Inc (RCUS)
|
|
Mar 20
|
Insider Sell: COO Jennifer Jarrett Sells 13,449 Shares of Arcus Biosciences Inc (RCUS)
|
|
Jan 16
|
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
|
|
Dec 9
|
We Think Arcus Biosciences (NYSE:RCUS) Needs To Drive Business Growth Carefully
|
|
Dec 7
|
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
|
|
Dec 5
|
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
|
|
Dec 4
|
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
|